Change of owner structure in Spago Nanomedical
Chairperson, CEO, and several major shareholders increase holding in Spago Nanomedical when 756,000 shares, ca. 9% of company total, are traded.
Mikael Lönn buys 80,000 shares and increase holding to 600,000 (7.0%) shares. Ranny Davidoff increases his holding by 150,000 shares to 200,000 (2.3%) in total. Several other owners, including Tiel Ridderstad and Mikael Hjorth, also increase their holding. Hans von Kantzows Stiftelse och Jan Lundström, among others, enter as new shareholders.
Chairperson Eva Redhe buys 42,000 shares. Since beginning of November, Redhe has increased her holding with more than 200,000 shares in total. Her current holding is 682,171, corresponding to 7.9%. Redhe is thereby the second largest shareholder of the company.
CEO Mats Hansen increases his holding by 10,000 shares, and board member Peter Wulff, elected earlier this year, increases his holding by 8,000 shares.
On December 7, Spago Nanomedical appointed product candidate in the SpagoPix-project, a critical step for the project that involved finalization of the formulation for regulatory development. Preparations for regulatory preclinical tox- and safety studies required prior to clinical trials is ongoing.
The seller is Nortal Investments AB, who subsequent to the sale does not retain any shares in the company.
For further information, contact Mats Hansen, CEO Spago Nanomedical AB, +46 767 764294, firstname.lastname@example.org.
Spago Nanomedical (AktieTorget Stockholm: SPAG) develops nanomaterials for cancer diagnostics and therapy. The company´s development activities are primarily focused on the cancer selective MRI-contrast agent SpagoPix, and the Tumorad®-project for cancer selective radionuclide therapy of cancer. The business concept of Spago Nanomedical is to develop projects from explorative to regulatory preclinical or early clinical phase, and then out-license or enter partnership for continued development of the projects to market launch. Spago Nanomedical collaborates with well-established and reputable patent consultants to continuously strengthen the intellectual property protection of the projects.
The aim of SpagoPix is to improve cancer diagnostics using magnetic resonance imaging (MRI) by facilitating early discovery of tumors and metastases. Early discovery improves the chances of efficient treatment and survival of cancer patients. Tumorad® is a further development of the company´s proprietary nanoparticles with the purpose of delivering radionuclides for tumor selective radiation therapy of cancer. Access to new therapies is essential for effective treatment of many forms of cancer.
The information in this press release is such that Spago Nanomedical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU, 596/2014). The information was submitted for publication, through the agency of the contact person set out above, at 11:10 on 7 December, 2016.
For further information, see www.spagonanomedical.se.